Documentation of frequent mutations in BRCA1 and BRCA2 as well as in vitro efficacy against cervical cancer cells grants biological plausibility to the targeted treatment of cervical cancer with PARP-inhibitors, as well as for routine tumor genomic assessment of cervical cancer specimens. Here, BRCA2 is linked to cervical cancer.